Hepatitis C: When High Drug Prices Preclude Patient Benefit

Cancer - United States
doi 10.1002/cncr.31292
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Strategies to Preclude Hepatitis C Virus Entry

2017English

MA07.11 Drug Price Comparison in Advanced Lung Cancer – High Cost Prices Is Accompanied by Patient Benefits?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

High Cancer Drug Prices 4 Years Later-Progress and Prospects

Cancer
Cancer ResearchOncology
2017English

Formal Patient Education Improves Patient Knowledge of Hepatitis C in Vulnerable Populations

Digestive Diseases and Sciences
PhysiologyGastroenterology
2010English

Patient-To-Patient Transmission of Hepatitis C Virus (HCV) During Colonoscopy Diagnosis

Virology Journal
VirologyInfectious Diseases
2010English

When to Search for Occult Infection After Eradication of Hepatitis C?

Gastroenterology
HepatologyGastroenterology
2017English

Comparison of the Mechanisms of Drug Resistance Among HIV, Hepatitis B, and Hepatitis C

Viruses
VirologyInfectious Diseases
2010English

Screening Urged for Hepatitis C but Drug Costs Are Prohibitive

CMAJ
Medicine
2014English

Investigation of Possible Patient-To-Patient Transmission of Hepatitis C in a Hospital

New South Wales Public Health Bulletin
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy